Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Product/R&D News
Thailand in talks with Chinese firms to produce inflenza vaccine
11/7/2005
Faced with a shortage of the best available antiviral drug against bird flu, Tamiflu, and other influenza vaccines, experts say Thailand should look for alternatives in preparing for a possible bird flu pandemic. At present, the country has in stock around 660,000 tablets of the anti-viral drug oseltamivir, the generic name for Tamiflu, and around 170,000 doses of flu vaccine.
The Government Pharmaceutical Organisation (GPO) plans to produce around one million capsules of the generic version of Tamiflu by next year. The Thai version would reduce the price per capsule from 120 baht to 70 baht.
The GPO is also negotiating with French and Chinese pharmaceutical firms to produce influenza vaccines in Thailand.
Mongkol Jivasantikarn, GPO's managing director, said cooperation with China's Sinovac Biotech was possible.
A team of health officials from the GPO and the Medical Science Department would visit China on Nov 16 to talk to the company, he said. Dr Mongkol admitted it would take at least three years for an influenza vaccine to be made here.
Relate News
more
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit